BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, May 26, 2026
Home » Newsletters » BioWorld MedTech

BioWorld MedTech

June 25, 2021

View Archived Issues
Smartphone displaying different views of the Voluntis app

Aptar to expand digital therapeutics assets with Voluntis buy

PARIS – Aptargroup Inc. is negotiating to buy Voluntis SA in a move that would complement its existing digital solutions portfolio and expand services to address multiple conditions and chronic diseases. "By being part of Aptar, we will be able to pursue a common ambition aimed at providing a complete digital health platform combining connected devices and digital therapeutics," Pierre Leurent, CEO and co-founder of Voluntis, told BioWorld. Read More
cloud-cybersecurity.png

U.S. lacks cyber oversight of hospitals’ networked medical devices

As cyberattacks on U.S. hospitals continue to increase with health care’s growing reliance on technology, a new report from the U.S. Office of Inspector General (OIG) has flagged Medicare’s requirements for being silent on the cybersecurity of networked medical devices. The OIG’s study found hospitals are not required to identify networked device cybersecurity in their emergency preparedness risk assessments, and as a result, they don’t include this information “very often.” Read More
US-Washington-congress-senate-house.png

House, Senate resurrect legislation for FDA regulation of LDTs

The U.S. Senate and the House of Representatives have reintroduced the Verifying Leading-edge IVCT Development (VALID) Act, a bill that would authorize the FDA to regulate lab-developed tests (LDT). The question of the agency’s statutory authority to regulate LDTs is part of a long-running debate, but the immediate question is whether Congress will see fit to deal with the question this year rather than wait until 2022, when the next device user fee will require legislative authorization. Read More
Tiny 3D-printed bioscaffold on gloved finger

Australian researchers outsmart 3D printers by printing biomaterials in empty space

PERTH, Australia – Researchers at RMIT University and St. Vincent's Hospital in Melbourne have flipped traditional 3D printing to create more intricate biomedical structures, advancing new technologies for regrowing bones and tissue. Instead of making the bioscaffolds directly, the team 3D printed molds with intricately patterned cavities and then filled them with biocompatible materials, before dissolving the molds away. Read More
US-budget-spending-money.png

House committee adds 8% to FDA budget authority for FY 2022

The U.S. House Appropriations subcommittee passed an appropriations bill for the FDA that would add $257 million to the agency’s budget authority for fiscal year 2022, an increase of 8% over the currently enacted level. The Alliance for a Stronger FDA said in a June 25 statement that it will work to ensure the Senate comes up with similar numbers, characterizing the push to fully fund the agency as “a multi-year marathon, not a sprint.” Read More

Appointments and advancements for June 25, 2021

New hires and promotions in the med-tech industry, including: Akoya Biosciences, Boston Scientific, Cequr, Neux, Pixium Vision, Quantgene, Vifor Pharma. Read More

Financings for June 25, 2021

Med-tech firms raising money in public or private financings, including: G Medical Innovations, Nyxoah, Teknova. Read More

In the clinic for June 25, 2021

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Histoindex. Read More

Med-tech gainers and losers for June 21-25, 2021

The top 10 med-tech stock gainers and losers for the week. Read More

Other news to note for June 25, 2021

Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: BGI Genomics, Health Catalyst, Joimax, Lucida, Marco Ophthalmic, Natera, Nexcelom, Olleyes, Perkinelmer, Skylinedx, Twistle. Read More

Regulatory actions for June 25, 2021

Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Axonics, Peijia Medical. Read More

BioWorld MedTech Patent Highlights: Week 24

BioWorld MedTech presents Patent Highlights, an excerpt of the most important med-tech patents from this week's Cortellis Patents Gazette. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 22, 2026.
  • Brain and DNA

    Sangamo presents primate data for prion suppressor ST-506

    BioWorld Science
    Sangamo Therapeutics Inc. discussed gene regulation approaches for neurodegenerative diseases when presenting findings on their clinical candidate ST-506 for the...
  • TREM2 agonists detailed in Pfizer patent

    BioWorld Science
    Pfizer Inc. has reported new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for the treatment of neurodegeneration.
  • Red dart and target against blue sky

    Unmasking the X: EPAC2 shifts the fragile X landscape

    BioWorld
    Researchers at UCLA have shown that divergent neuronal signaling in fragile X mice converges on EPAC2, a druggable target whose inhibition restores circuit...
  • Skin irritation on hands

    Recludix presents STAT1/3 inhibitors for dermatological diseases

    BioWorld Science
    Recludix Pharma Inc. recently presented data on their new STAT1/3 inhibitors REX-6553 and REX-6547 for treating dermatological inflammatory skin diseases.
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing